WASHINGTON — A significant shift in the treatment paradigm for high-risk non-muscle-invasive bladder cancer (NMIBC) appears to be on the horizon. New findings from the Phase III POTOMAC trial, presented at the American Urological Association (AUA) annual meeting, suggest that integrating durvalumab (Imfinzi) into standard Bacillus Calmette-Guérin (BCG) regimens can meaningfully delay disease progression and reduce the burden of surgical intervention for patients.
For decades, the standard of care for high-risk NMIBC has remained largely stagnant: BCG induction followed by maintenance therapy. While effective for many, a significant portion of patients face recurrence or progress to muscle-invasive disease, eventually requiring radical cystectomy—a life-altering surgery involving the removal of the bladder. The POTOMAC trial data provides a robust clinical rationale for incorporating immunotherapy to improve these outcomes.
The Clinical Challenge: Why NMIBC Demands Innovation
Non-muscle-invasive bladder cancer is characterized by its high propensity for recurrence. Even with optimal BCG treatment, patients often cycle through recurrences, creating a chronic state of clinical anxiety and frequent endoscopic surveillance. The "high-risk" classification implies a significant probability of progression to muscle-invasive disease, which carries a much poorer prognosis.
The POTOMAC study, a massive global effort involving 1,018 patients across 116 sites in 12 countries, was designed to test whether the addition of the PD-L1 inhibitor durvalumab could "prime" the immune system to respond more effectively to the localized inflammatory response induced by BCG. With a patient demographic that was 80% male and an average age of 67–68, the study captured a representative slice of the real-world urologic oncology population.
Chronology: A Multi-Year Path to Efficacy
The journey toward these results has been defined by rigorous data collection and long-term patient monitoring.
- Trial Initiation: The POTOMAC trial (NCT03528694) began with the goal of testing three distinct arms: durvalumab plus BCG induction and maintenance, durvalumab plus BCG induction only, and the standard control arm of BCG induction and maintenance alone.
- Primary Endpoint Achievement: Initial findings released previously established that the combination therapy successfully hit its primary endpoint, demonstrating a 32% reduction in the risk of disease recurrence or death (HR 0.68; 95% CI 0.50–0.93; P=0.015).
- The 2026 AUA Presentation: At this year’s AUA meeting, Dr. Neal Shore of the Carolina Urologic Research Center provided the latest longitudinal analysis. This presentation focused on the first-year "milestone" data, which highlights the critical window where high-risk NMIBC patients are most vulnerable to recurrence.
Supporting Data: By the Numbers
The latest analysis from the POTOMAC trial paints a compelling picture of improved disease control. The metrics shared by Dr. Shore provide a granular look at why the combination of durvalumab and BCG is being viewed as a potential new standard of care.
Delaying the High-Risk Event
In the first year of treatment, 16% of the 339 patients receiving the durvalumab-BCG combination experienced a high-risk disease event. In contrast, 20% of the 340 patients in the BCG-alone cohort saw their disease return or progress within that same timeframe.
More importantly, the median time to a high-risk event was substantially extended: 14.1 months in the durvalumab arm versus only 8.3 months in the control arm. This delay represents a significant improvement in quality of life, effectively pushing back the need for secondary salvage therapies.
Impact on Cystectomy Rates
Perhaps the most clinical meaningful data point is the impact on surgical outcomes. For patients whose disease becomes unresponsive to BCG—a major clinical failure—the risk of needing a cystectomy is a constant threat. In the POTOMAC trial, only 8% of the BCG-unresponsive patients in the durvalumab arm proceeded to cystectomy, compared to 25% in the BCG-only group. Across the entire cohort, the rate of cystectomy was 4% for those on the durvalumab regimen versus 6% for those on standard care.
Subgroup Success
In patients with papillary-only disease, which constituted 65% of the study population, the results were even more pronounced. The combination therapy yielded a 39% to 52% reduction in the risk of recurrence or death across various papillary tumor subtypes, confirming that the treatment is broadly effective across different tumor morphologies.
Official Perspectives and Clinical Interpretation
Dr. Neal Shore, the lead investigator, was categorical in his assessment of the data. During his presentation, he noted that the clinical benefit is sufficient to support a shift in clinical practice.
"The data clearly support one year of durvalumab in combination with BCG induction and maintenance as a potential new treatment for patients with BCG-naive, high-risk NMIBC," Dr. Shore stated. He added a critical caveat, however: the implementation of this regimen must involve a "shared decision-making conversation."
This emphasis on shared decision-making acknowledges that while the efficacy is superior, the side-effect profile of immunotherapy is distinct from the traditional inflammatory reactions associated with BCG. Urologists and patients must weigh the lower recurrence risk against the potential for immune-related adverse events (irAEs).
Implications for Practice and Patient Management
The move toward immunotherapy in the NMIBC space requires a change in how urologists monitor their patients.
Managing the Safety Profile
The POTOMAC trial demonstrated a clear increase in immune-mediated adverse events (irAEs). While 97% of patients in the durvalumab arm experienced any-cause adverse events compared to 91% in the BCG-only arm, the severity and nature of those events differed. Grade 3 or 4 treatment-related adverse events occurred in 21% of the durvalumab cohort compared to 4% in the control group.
The most common immune-mediated events included:
- Hypothyroidism (11%)
- Hepatic events (5%)
- Dermatitis/Rash (3%)
- Hyperthyroidism and Thyroiditis (2% each)
Dr. Shore noted that these events are generally manageable and consistent with the known safety profile of durvalumab in other oncology indications. However, he emphasized that clinicians must become "comfortable" with recognizing and treating these immune-related issues. Encouragingly, 67% of these irAEs had resolved by the time of the data cutoff, suggesting that with proactive monitoring, the long-term impact on patient health is minimal.
The Future of Bladder Cancer Care
The POTOMAC trial represents a landmark moment for NMIBC research. By extending the interval between recurrences and significantly reducing the number of patients who must undergo radical cystectomy, the durvalumab-BCG combination addresses the two greatest clinical needs in the field.
As the oncology community digests these findings, the conversation will likely shift toward identifying which specific high-risk patients stand to gain the most from this combination. With a 32% reduction in recurrence/death risk and a clearer path to avoiding surgery, the trial provides a strong argument for moving beyond the "BCG-only" era.
For the thousands of patients currently navigating the uncertainty of high-risk NMIBC, the POTOMAC data offers something that has been in short supply: a viable, evidence-backed strategy to stop the cycle of recurrence and preserve bladder function. The next phase of integration will involve incorporating these findings into updated clinical guidelines, likely positioning immunotherapy as a cornerstone of the modern urologic oncology toolkit.
